Coya Therapeutics, Inc. COYA
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -6.54% | -23.29% | -42.64% | -72.29% | -101.38% |
| Total Depreciation and Amortization | -29.41% | -14.71% | 0.00% | 0.00% | 0.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 106.86% | 132.94% | 144.74% | 92.91% | 102.60% |
| Change in Net Operating Assets | -1,171.17% | 50.64% | 106.79% | 199.62% | -88.59% |
| Cash from Operations | 4.56% | 7.49% | -4.38% | -19.98% | -139.61% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -4,558.40% | -136.48% | 100.00% |
| Cash from Investing | -- | -- | -4,558.40% | -136.48% | 100.00% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 222.96% | 111.05% | 25.73% | -68.30% | -68.37% |
| Repurchase of Common Stock | 25.75% | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | 100.00% | 100.00% |
| Cash from Financing | 223.12% | 111.85% | 27.20% | -68.11% | -68.41% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 296.89% | 3,412.40% | 48.49% | -114.51% | -129.05% |